Complement activation, endothelial dysfunction, insulin resistance and chronic heart failure

Scandinavian Cardiovascular Journal

Volumn 44, Issue 5, 2010, Pages 260-266

  Bjerre, Mette ^a   Kistorp, Caroline ^b   Hansen, Troels Krarup ^a   Faber, Jens ^b   Lip, Gregory Y H ^c   Hildebrandt, Per ^d   Flyvbjerg, Allan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^d Department of Medicine ^*  (Denmark)

Author keywords

Chronic heart failure; Complement; E selectin; Insulin resistance; Soluble MAC

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INSULIN; VON WILLEBRAND FACTOR;

AGED; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART FAILURE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; DIABETES MELLITUS; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 78649238269     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2010.484506     Document Type: Article

References (28)

1. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J. 2005;26:65-9.
2. Kistorp C, Chong AY, Gustafsson F, Galatius S, Raymond I, Faber J, et al. Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. Eur J Heart Fail. 2008;10:380-7.
3. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983-92.
4. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: A comprehensive appraisal. Cardiovasc Diabetol. 2006;5:4.
5. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocr Rev. 2001;22:36-52.
6. Vila V, Martinez-Sales V, Almenar L, Lazaro IS, Villa P, Reganon E. Infl ammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients. Int J Cardiol. 2008;130:276-7.
7. Rathcke CN, Kistorp C, Raymond I, Hildebrandt P, Gustafsson F, Lip GY, et al. Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand Cardiovasc J. 2010;44:92-9.
8. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756-62.
9. Clark DJ, Cleman MW, Pfau SE, Rollins SA, Ramahi TM, Mayer C, et al. Serum complement activation in congestive heart failure. Am Heart J. 2001;141:684-90.
10. Bjerre M, Hansen TK, Flyvbjerg A. Complement activation and cardiovascular disease. Horm Metab Res. 2008;40:626-34.
11. Fosbrink M, Niculescu F, Rus H. The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res. 2005;31:37-46.
12. Yasuda M, Takeuchi K, Hiruma M, Iida H, Tahara A, Itagane H, et al. The complement system in ischemic heart disease. Circulation. 1990;81:156-63.
13. Di Marzio D, Mohn A, de Martino M, Chiarelli F. Macroangiopathy in adults and children with diabetes: Risk factors (part 2). Horm Metab Res. 2006;38:706-20.
14. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294:334-41.
15. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver MF. Insulin resistance in chronic heart failure. Eur Heart J. 1994;15:1528-32.
16. Kistorp C, Galatius S, Gustafsson F, Faber J, Corell P, Hildebrandt P. Prevalence and characteristics of diabetic patients in a chronic heart failure population. Int J Cardiol. 2005;100:281-7.
17. Haahr-Pedersen S, Bjerre M, Flyvbjerg A, Mogelvang R, Dominquez H, Hansen TK, et al. Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primar y percutaneous coronary inter vention. J Invasive Cardiol. 2009;21:13-9.
18. Thiel S, Moller-Kristensen M, Jensen L, Jensenius JC. Assays for the functional activity of the mannan-binding lectin pathway of complement activation. Immunobiology. 2002;205:446-54.
19. Yki-Jarvinen H. Insulin resistance and endothelial dysfunction. Best Pract Res Clin Endocrinol Metab. 2003;17:411-30.
20. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infl iximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-40.
21. Anker SD, Coats AJ. How to RECOVER from RENAIS-SANCE? The signifi cance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86:123-30.
22. Zimmermann O, Bienek-Ziolkowski M, Wolf B, Vetter M, Baur R, Mailander V, et al. Myocardial infl ammation and non-ischaemic heart failure: Is there a role for C-reactive protein? Basic Res Cardiol. 2009;104:591-9.
23. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95:3.
24. Dominguez H, Flyvbjerg A. Insulin resistance: The cardiovascular aspect. Horm Metab Res. 2008;40:583-7.
25. Cosentino F, Luscher TF. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol. 1998;32(Suppl 3):S54-S61.
26. Wisniacki N, Taylor W, Lye M, Wilding JP. Insulin resistance and infl ammatory activation in older patients with systolic and diastolic heart failure. Heart. 2005;91:32-7.
27. Duncan ER, Crossey PA, Walker S, Anilkumar N, Poston L, Douglas G, et al. Effect of endothelium-specifi c insulin resistance on endothelial function in vivo. Diabetes. 2008;57:3307-14.
28. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894-8.